Scitherm

SciTherm is a preclinical-stage biotechnology company dedicated to the development of novel therapeutic candidates for the treatment of obesity and related metabolic diseases. The company utilizes a computational approach, involving in-silico molecular design and enzymatic synthesis, to engineer small-molecule thermogenics. These candidates are designed to specifically activate lipid and triglyceride degradation pathways in adipocytes, promoting fat reduction without the adverse secondary effects often associated with traditional thermogenic agents. Their platform integrates metagenomic analysis and in-vitro lipolysis assays to validate efficacy and target specificity. By focusing on these pathways, SciTherm aims to provide a safe, effective pharmacological solution to combat obesity and its associated comorbidities.

The company's work is critical for patients and healthcare providers seeking new, durable metabolic treatments that move beyond caloric restriction. By leveraging scientific expertise in biocatalysis and thermogenesis, SciTherm aims to address the root cause of fat accumulation. The company, which is supported by early-stage investors like GridX, is currently focused on selecting lead candidates for preclinical development. The effectiveness of their approach is supported by experimental data demonstrating significant reductions in triglyceride levels within adipocytes, positioning them as an innovative player in the landscape of metabolic disease drug development.